These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
261 related items for PubMed ID: 26472021
61. Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms. Solomon JP, Hechtman JF. Cancer Res; 2019 Jul 01; 79(13):3163-3168. PubMed ID: 31196931 [Abstract] [Full Text] [Related]
62. [Clinicopathological features of gastric carcinomas with NTRK-rearrangement/amplification: report of four cases]. Xu AD, Fu Y, Pu XH, Wu HY, Sun Q, Fan XS. Zhonghua Bing Li Xue Za Zhi; 2023 May 08; 52(5):454-459. PubMed ID: 37106286 [Abstract] [Full Text] [Related]
63. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro. Tatematsu T, Sasaki H, Shimizu S, Okuda K, Shitara M, Hikosaka Y, Moriyama S, Yano M, Brown J, Fujii Y. Mol Clin Oncol; 2014 Sep 08; 2(5):725-730. PubMed ID: 25054037 [Abstract] [Full Text] [Related]
64. Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. Greco A, Miranda C, Pagliardini S, Fusetti L, Bongarzone I, Pierotti MA. Genes Chromosomes Cancer; 1997 Jun 08; 19(2):112-23. PubMed ID: 9172002 [Abstract] [Full Text] [Related]
68. Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer. Houang M, Toon CW, Clarkson A, Sioson L, Watson N, Farzin M, Selinger CI, Chou A, Morey AL, Cooper WA, O'Toole SA, Gill AJ. Pathology; 2014 Aug 08; 46(5):383-8. PubMed ID: 24842379 [Abstract] [Full Text] [Related]
69. Primary NTRK-rearranged Spindle Cell Neoplasm of the Lung: A Clinicopathologic and Molecular Analysis of 3 Cases. Zhu P, Wang J. Am J Surg Pathol; 2022 Jul 01; 46(7):1007-1013. PubMed ID: 35220354 [Abstract] [Full Text] [Related]
74. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment. Li W, Zhang J, Guo L, Chuai S, Shan L, Ying J. J Thorac Oncol; 2017 Jan 01; 12(1):94-101. PubMed ID: 27614248 [Abstract] [Full Text] [Related]
75. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?]. Ouali K, Pellat A, Cohen R, Svrcek M, Penault-Llorca F, André T. Bull Cancer; 2020 Apr 01; 107(4):447-457. PubMed ID: 32067719 [Abstract] [Full Text] [Related]
78. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, Lee JS, Jheon S, Chung JH. J Thorac Oncol; 2011 Mar 01; 6(3):466-72. PubMed ID: 21258247 [Abstract] [Full Text] [Related]
79. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization. Williams AS, Greer W, Bethune D, Craddock KJ, Flowerdew G, Xu Z. Virchows Arch; 2016 Nov 01; 469(5):533-540. PubMed ID: 27562706 [Abstract] [Full Text] [Related]
80. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia. Smith KM, Fagan PC, Pomari E, Germano G, Frasson C, Walsh C, Silverman I, Bonvini P, Li G. Mol Cancer Ther; 2018 Feb 01; 17(2):455-463. PubMed ID: 29237803 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]